Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in PortugalCost-effectiveness of new oral anticoagulants in Portuguese atrial fibrillation patients | Revista Portuguesa de Cardiologia (English edition)

Statistics

Original Article

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in PortugalCost-effectiveness of new oral anticoagulants in Portuguese atrial fibrillation patients

Custo-efetividade dos novos anticoagulantes orais na fibrilhação auricular em Portugal

João Costaa,b,c,

Corresponding author

jncosta@medicina.ulisboa.pt

Corresponding author.

, Francesca Fiorentinoa, Daniel Caldeirab,c,d, Mónica Inêse, Catarina Lopes Pereiraa, Luís Pinheirof, António Vaz-Carneiroa, Margarida Borgesa,b,g, Miguel Gouveiah

a Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal

b Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal

c Unidade de Farmacologia Clínica, Instituto de Medicina Molecular, Lisboa, Portugal

d Serviço de Cardiologia, Hospital Garcia de Orta, Almada, Portugal

e Health & Value Department, Laboratórios Pfizer Lda, Porto Salvo, Portugal

f Serviço de Medicina 2, Centro Hospitalar Lisboa Norte EPE, Portugal

g Unidade de Farmacologia Clínica, Centro Hospitalar de Lisboa Central EPE, Portugal

h Católica Lisbon School of Business and Economics, Lisboa, Portugal

Read

8568

Times
was read the article

2295

Total PDF

6273

Total HTML

Share statistics

Article information

ISSN: 21742049
Original language: English

DOI:10.1016/j.repce.2015.11.005

The statistics are updated each day

Year/Month	Html	Pdf	Total

2025 6	13	2	15
2025 5	70	21	91
2025 4	80	29	109
2025 3	84	23	107
2025 2	52	23	75
2025 1	54	51	105
2024 12	47	25	72
2024 11	63	31	94
2024 10	47	34	81
2024 9	31	27	58
2024 8	42	25	67
2024 7	37	30	67
2024 6	31	20	51
2024 5	32	26	58
2024 4	38	27	65
2024 3	35	19	54
2024 2	31	22	53
2024 1	25	24	49
2023 12	17	26	43
2023 11	30	20	50
2023 10	16	28	44
2023 9	37	23	60
2023 8	33	19	52
2023 7	29	11	40
2023 6	33	17	50
2023 5	71	27	98
2023 4	47	3	50
2023 3	49	28	77
2023 2	44	19	63
2023 1	36	18	54
2022 12	63	24	87
2022 11	57	19	76
2022 10	64	29	93
2022 9	40	26	66
2022 8	85	35	120
2022 7	58	92	150
2022 6	81	37	118
2022 5	60	32	92
2022 4	41	26	67
2022 3	53	43	96
2022 2	42	35	77
2022 1	60	37	97
2021 12	70	39	109
2021 11	65	40	105
2021 10	32	34	66
2021 9	18	20	38
2021 8	18	33	51
2021 7	32	17	49
2021 6	44	12	56
2021 5	59	35	94
2021 4	75	34	109
2021 3	76	23	99
2021 2	71	13	84
2021 1	40	17	57
2020 12	36	10	46
2020 11	56	14	70
2020 10	32	17	49
2020 9	60	12	72
2020 8	41	10	51
2020 7	84	20	104
2020 6	54	11	65
2020 5	56	8	64
2020 4	57	10	67
2020 3	90	14	104
2020 2	142	43	185
2020 1	36	9	45
2019 12	70	16	86
2019 11	36	13	49
2019 10	35	8	43
2019 9	75	10	85
2019 8	45	10	55
2019 7	61	11	72
2019 6	48	24	72
2019 5	37	10	47
2019 4	42	15	57
2019 3	49	14	63
2019 2	70	8	78
2019 1	68	11	79
2018 12	87	9	96
2018 11	214	16	230
2018 10	567	20	587
2018 9	78	16	94
2018 8	38	8	46
2018 7	31	4	35
2018 6	34	8	42
2018 5	49	7	56
2018 4	27	7	34
2018 3	52	6	58
2018 2	22	7	29
2018 1	22	10	32
2017 12	48	10	58
2017 11	50	19	69
2017 10	49	14	63
2017 9	28	14	42
2017 8	37	7	44
2017 7	99	5	104
2017 6	41	9	50
2017 5	45	12	57
2017 4	20	3	23
2017 3	43	18	61
2017 2	59	11	70
2017 1	45	6	51
2016 12	46	17	63
2016 11	39	10	49
2016 10	51	14	65
2016 9	51	18	69
2016 8	29	2	31
2016 7	26	10	36
2016 6	5	19	24
2016 5	14	8	22
2016 4	54	22	76
2016 3	62	46	108
2016 2	70	53	123
2016 1	103	52	155

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter